MAY 12, 2016 03:00 PM PDT

Using big data to interpret genomes for diagnostics, therapeutics, and precision medicine

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Assistant Professor, Director of Clinical Genome Informatics, Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mou
    Biography
      r. Chen is Director of Clinical Genome Informatics (http://rongchenlab.org) at Icahn Institute of Genetics and Multiscale Biology. His research focuses on developing databases, genome repositories, and clinical applications to interpret personal genomes for clinical diagnosis, precision medicine, predictive disease risk, and novel therapeutics.

      Prior to Mount Sinai, he led the collaborative efforts at Stanford University to drive personalized medicine and clinical diagnosis on Mendelian and complex diseases using genome and exome sequencing. Dr. Chen also helped launch a startup company Personalis, which won the VA's contract for the Million Veteran Genome project.

      Dr. Chen has a broad interest in translational bioinformatics and genome interpretation, and has published over 80 papers in Lancet, Cell, Nature Biotechnology, Nature Methods, Science Translational Medicine, PNAS, AJHG, JCI, PLoS Genetics, PLoS Computational Biology, Genome Research, Genome Biology, Genome Medicine, and AJT. He holds numerous patents for software and databases on personalized medicine, diagnosis, and structure modeling.

    Abstract:

    Millions of individuals have been sequenced or genotyped and linked with medical records, providing an exciting opportunity for therapeutic target discovery. My lab has been using a resilience approach to learn from success instead of failure, and analyzed hundreds of thousands of genomes with electronic medical records to drive target discovery for childhood Mendelian diseases, Alzheimer’s disease, and cardiovascular traits.

    I will describe how we analyzed 589,305 genomes and identified 13 genetic super heroes who carry fully penetrant childhood Mendelian diseases but are healthy in our recent resilience project, and how we decoded individuals who carry APOE e4/e4 risk variants but are resilient for Alzheimer’s disease. I will further describe how we analyzed individuals who have a loss of gene but carry favorable cardiovascular traits, identified potential therapeutic targets to lower fasting glucose levels, and validated the effects in mice.

    Learning objectives:

    • How to interpret genetic variants using 150,000 genomes from diseased and healthy cohorts, and variants with validated molecular functional impact from 30 million literature.
    • How to use resilient approach to interpret thousands of genomes with medical records for therapeutic target discovery.

    Show Resources
    You May Also Like
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...